Operating Segments (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Segment reporting
Revenues	$ 2,342	$ 206,929	$ 119,371	$ 464,107
Income (loss) from Operations	(1,744,675)	(1,630,324)	(3,861,766)	(3,781,013)
Amortization and Depreciation Expense	1,588	1,590	3,176	3,375
Other (Expense) Income, Net	100,173	18,300	301,937	(38,317)
Share-Based Compensation	57,675	90,042	117,636	163,676
Identifiable Assets	9,865,079		$ 9,865,079		$ 9,797,326
Number of operating segments | segment			2
Operating Segments [Member] | Specialized BioTherapeutics [Member]
Segment reporting
Revenues	2,342	68,505	$ 119,371	223,870
Income (loss) from Operations	(283,206)	(611,300)	(1,143,810)	(1,521,677)
Amortization and Depreciation Expense	953	954	1,906	2,025
Other (Expense) Income, Net	(31,346)	9,931	(23,806)	16,013
Share-Based Compensation	20,940	27,427	41,612	54,854
Identifiable Assets	183,858		183,858		272,099
Operating Segments [Member] | Public Health Solutions [Member]
Segment reporting
Revenues		138,424		240,237
Income (loss) from Operations	(62,052)	(2,247)	(108,049)	(1,820)
Amortization and Depreciation Expense	159	159	318	337
Share-Based Compensation	617	994	1,205	1,988
Identifiable Assets	2,917		2,917		3,976
Corporate [Member]
Segment reporting
Income (loss) from Operations	(1,399,417)	(1,016,777)	(2,609,907)	(2,257,516)
Amortization and Depreciation Expense	476	477	952	1,013
Other (Expense) Income, Net	131,519	8,369	325,743	(54,330)
Share-Based Compensation	36,118	$ 61,621	74,819	$ 106,834
Identifiable Assets	$ 9,678,304		$ 9,678,304		$ 9,521,251